This result is perhaps not surprising given that most current TB vaccine candidates were designed to specifically target induction of IFNγ-expressing CD4 T cells, predicated on the well-established evidence that Th1 cells are necessary, although not sufficient, for protective immunity against M. tb, based on animal models and human studies(reviewed in [5, 6, 24]). The gene discussed is CD4; the disease is tuberculosis.